A batch of HAp powder passes XRD, particle-size, and chemical-composition testing before sterilization. After sterilization, is it still the same material?
This question cannot be answered from sterilization records or sterility results alone. Sterilization is first a microbiological control step, but for bioceramics and composite biomaterials it is also a thermal, irradiation, or chemical process. The main crystalline phase may remain unchanged while the surface state, gel network, polymer molecular weight, pore structure, or package environment has shifted.
Meeting a defined sterility assurance target does not automatically mean the material remains acceptable. One question concerns microbiological control; the other concerns whether the product remains within its predefined material and functional acceptance criteria after sterilization.
Start with the system, not only the material name
When discussing sterilization effects on HAp/CaHA, the first distinction is between a single ceramic phase and a complete material system.
Sintered dense HAp ceramics, HAp powders, HAp microspheres, porous calcium-phosphate scaffolds, HAp coatings, HAp/polymer composites, and CaHA microsphere gel systems may all be described as hydroxyapatite-containing materials. Their responses to sterilization can differ substantially.
A pure ceramic phase may be relatively stable under certain sterilization conditions. Once HAp or CaHA is combined with PLA, PLGA, collagen, chitosan, CMC, HA gel, or a packaging system, the more sensitive part may be the organic phase, the particle-carrier interface, or the overall physical structure. The same HAp/CaHA microspheres may require different post-sterilization checks when used as dry powder, dispersed in a CMC gel, or incorporated into a PLGA scaffold, even if XRD shows no obvious phase change.
Whether HAp can tolerate a sterilization method is therefore not the same question as whether a HAp/CaHA-containing composite product system can use that method.
Each sterilization route changes a different risk profile
Steam sterilization is mature, widely used, and free of ethylene oxide residual concerns. It also brings heat and moisture. For fully sintered dense HAp ceramics, routine steam-sterilization temperatures are far below typical sintering temperatures, so major bulk-phase transformation may not be the primary concern. Moisture exposure, porosity, surface properties, and minor phases still require material-specific evaluation. For polymers, gels, and composite scaffolds, hydrolysis, swelling, shrinkage, pore changes, and mechanical-property shifts may matter more [2][5].
Gamma irradiation, electron beam, and X-ray processing are ionizing radiation technologies. They are lower-temperature routes and can be suitable for many disposable devices and packaged systems, but low temperature does not mean no material change. The Hossain et al. study on HAp and HAp composites with nanocellulose and chitosan used gamma irradiation up to 200 kGy; that is useful as material-characterization evidence, but it should not be treated as direct evidence for routine terminal-sterilization doses in a finished product [3]. In polymer-containing systems, chain scission and crosslinking may occur together, influencing molecular weight, elasticity, degradation rate, and drug stability [1][4].
Ethylene oxide offers low-temperature processing and strong penetration into many complex packages. The key issue is usually not whether the HAp phase transforms, but how residuals, aeration, adsorption, and desorption are controlled. Porous materials, high-surface-area particles, gels, and packages can all complicate residual behavior [2].
| Method | Main advantage | Key questions for HAp/CaHA systems |
|---|---|---|
| Steam | Mature process, no chemical residuals | Polymer hydrolysis, gel rheology, pore structure, mechanical behavior, package tolerance |
| Gamma irradiation | High penetration, low-temperature process | Crystallinity, surface defects, polymer scission or crosslinking, degradation behavior |
| Electron beam / X-ray | Potential low-temperature route for selected systems | Dose distribution, product thickness, and material compatibility of polymers and interfaces |
| Ethylene oxide | Useful for some heat-sensitive materials and complex packages | EO residuals, aeration time, adsorption/desorption, surface chemistry |
No method can be assigned to every HAp/CaHA system without product-specific validation. The same sterilization route may lead to different outcomes when formulation, packaging, moisture content, and geometry change.
Evidence level matters
Published studies can guide the discussion, but the evidence level needs to stay visible.
Studies on pure HAp or HAp composites are mainly material characterization studies. They help assess phase retention, surface state, defect structure, and composite changes before and after sterilization [3][4]. Literature on PLA devices, dental scaffolds, PLGA-PEG-HAp composites, and apatite cement points to possible changes in molecular weight, pore structure, hardness, setting time, composition, and mechanical behavior in specific systems [1][2][4][5].
These papers help identify which material parameters may be affected by sterilization. They do not replace product-specific formulation validation, packaging validation, sterility assurance validation, biological evaluation, or clinical research.
XRD alone is not enough after sterilization
XRD is important. It can show whether the main HAp phase remains, whether new calcium-phosphate phases appear, and whether crystallinity changes are visible. But if the system depends on more than crystal phase, the post-sterilization evaluation cannot stop at phase analysis.
For HAp/CaHA raw materials and downstream composite systems, the post-sterilization test matrix should follow the function of the material system rather than a copied checklist.
| Evaluation area | Typical checks | Question being answered |
|---|---|---|
| Structure and chemistry | XRD, FTIR, Ca/P ratio, crystallinity, minor phases, dissolution behavior | Whether composition and phase remain within the acceptable range |
| Particle and interface | Particle size distribution, SEM morphology, surface area, porosity, dispersion state | Whether microspheres, powders, or scaffolds show visible structural changes |
| System performance | Gel viscosity, rheology, injectability and extrusion-force testing, phase separation, polymer molecular weight, degradation behavior | Whether use-related performance remains stable in the composite system |
| Residuals, microbiological control, and stability | EO residuals, endotoxin, microbiological limits, package integrity, aging follow-up | Whether sterilization, packaging, and storage jointly meet validation needs |
The practical rule is simple: if a property supports the system's intended performance, that property should be rechecked after sterilization. When the target is microsphere morphology, SEM images also need transparent sample preparation, field selection, and statistical methods; this is consistent with our earlier discussion of CaHA microsphere SEM methodology.
Sterilization should enter early development
Many projects first finalize formulation and structure, then look for a sterilization route near the end. That sequence can be risky for HAp/CaHA-containing composite systems.
If steam sterilization disrupts the gel, gamma irradiation changes the polymer, or ethylene oxide requires an impractical aeration period, formulation, packaging, and even manufacturing flow may need to be revisited.
A better development sequence starts earlier: identify the most sensitive components, screen plausible sterilization routes, define critical quality attributes, compare pre- and post-sterilization data, and evaluate the product, packaging configuration, and sterilization process as an integrated system.
Sterilization is not only a final production step. For complex HAp/CaHA systems, it is part of product design.
Build a clear material baseline into the technical file
For downstream R&D teams, reliable sterilization validation starts from a stable material baseline.
Nanjing Junzhuo Biotechnology Co., Ltd. supplies HAp/CaHA microsphere and powder raw materials, β-TCP, and related calcium-phosphate bioceramics with attention to particle size distribution, microsphere morphology, phase purity, crystallinity, batch consistency, endotoxin control, microbiological limits, and documentation support. For fully dense HAp/CaHA microsphere samples, powders, and custom calcium-phosphate materials, clear characterization records help R&D teams build a pre- and post-sterilization comparison baseline.
The sterilization method, packaging system, sterility assurance level, and regulatory validation remain the responsibility of the product owner. The role of the material supplier is to provide traceable, comparable, and reviewable baseline data, not to replace finished-product sterilization validation.
For early planning around particle size, phase composition, morphology, batch documentation, or pre- and post-sterilization comparison items, teams can use Nanjing Junzhuo's custom development and documentation support as a starting point for technical discussion.
Conclusion
After sterilization, HAp/CaHA may or may not be “the same material,” depending on what is being evaluated.
The main crystalline phase may still be HAp/CaHA, while the complete system may have changed in properties that matter to formulation, handling, release, degradation, or stability. For pure ceramic phases, changes may be limited under certain conditions. For systems containing gels, polymers, drugs, proteins, or complex packages, the interface, organic phase, and overall structure often deserve closer attention.
Demonstrating post-sterilization stability is part of downstream HAp/CaHA product development.
This text is a technical discussion based on published literature. It describes evaluation boundaries for HAp/CaHA and related composite systems during sterilization and does not provide a sterilization protocol, regulatory advice, clinical recommendation, or treatment guidance for any specific medical product.
References
- Pérez Davila S, González Rodríguez L, Chiussi S, Serra J, González P. How to Sterilize Polylactic Acid Based Medical Devices? Polymers. 2021;13(13):2115. DOI: 10.3390/polym13132115.
- de Sousa Iwamoto L A, Duailibi M T, Iwamoto G Y, de Oliveira D C, Duailibi S E. Evaluation of ethylene oxide, gamma radiation, dry heat and autoclave sterilization processes on extracellular matrix of biomaterial dental scaffolds. Scientific Reports. 2022;12:4299. DOI: 10.1038/s41598-022-08258-1.
- Hossain M S, Shaikh M A A, Jahan S A, et al. Exploring the biomedical competency of gamma-radiation aided hydroxyapatite and its composite fabricated with nano-cellulose and chitosan. RSC Advances. 2023;13(14):9654–9664. DOI: 10.1039/D3RA00476G.
- Shahabi S, Najafi F, Majdabadi A, et al. Effect of Gamma Irradiation on Structural and Biological Properties of a PLGA-PEG-Hydroxyapatite Composite. The Scientific World Journal. 2014;2014:420616. DOI: 10.1155/2014/420616.
- Takechi M, Miyamoto Y, Momota Y, et al. Effects of various sterilization methods on the setting and mechanical properties of apatite cement. Journal of Biomedical Materials Research Part B: Applied Biomaterials. 2004;69B(1):58–63. DOI: 10.1002/jbm.b.10031.